Skip to main content
NMRA logo

NMRA · Neumora Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track NMRA — free
$0.33 -0.01 (-3.78%) At close · Nov 20 Play latest call Q4 2025 earnings call transcript
Market Cap
$63.01M
Shares
188.69M
Volume · Nov 20 1.06M Avg daily vol (3M) 1.67M

Neumora Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Neumora Therapeutics, Inc. (NMRA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Annual General Meeting
Investor event
2026-05-27
Neumora Therapeutics, Inc. (NMRA) May 27, 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-19
Neumora Therapeutics, Inc. (NMRA) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-04-13
Neumora Therapeutics, Inc. (NMRA) April 13, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-30
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
Confident tone NMRA-215 obesity program and rat tox findings M4 PAM franchise / NMRA-898 in schizophrenia NMRA-511 in Alzheimer's disease agitation
Results not yet reported
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-01-05
Neumora Therapeutics, Inc. (NMRA) January 5, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q2
2025-08-06
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Confident tone Obesity / NMRA-215 NLRP3 inhibitor lead indication M4 PAM franchise (NMRA-861, NMRA-898) Navacaprant KOASTAL Phase III in MDD
Diluted EPS
$-0.33
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript
Positive tone KOASTAL Phase 3 program (navacaprant in MDD) KOASTAL-1 failure and study modifications NMRA-511 in Alzheimer's disease agitation
Diluted EPS
$-0.42
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Neumora Therapeutics, Inc. (NMRA) Q4 2024 Earnings Call Transcript
Positive tone Navacaprant (KOASTAL Phase 3 program in MDD) Regulatory engagement and trial design Leadership transitions
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript
Confident tone Navacaprant / KOASTAL Phase 3 program in MDD Pipeline breadth and additional programs Clinical validation and safety profile
Diluted EPS
$-0.45
Audio Transcript Slides 8-K10-Q
Showing 1–9 of 9 webcasts
Key facts CIK 1885522 CUSIP 640979100 13F (30d) 143 filings 117 filers Visit website Investor relations